Should I buy or sell Madrigal Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MDGL shares. View MDGL analyst ratings or view top-rated stocks .

What is Madrigal Pharmaceuticals' stock price target for 2024?

10 equities research analysts have issued 12 month price objectives for Madrigal Pharmaceuticals' stock. Their MDGL share price targets range from $270.00 to $425.00. On average, they expect the company's stock price to reach $377.40 in the next twelve months. This suggests a possible upside of 78.0% from the stock's current price. View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts .

How have MDGL shares performed in 2024?

Madrigal Pharmaceuticals' stock was trading at $231.38 at the start of the year. Since then, MDGL stock has decreased by 8.4% and is now trading at $212.04. View the best growth stocks for 2024 here .

When is Madrigal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MDGL earnings forecast .

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) posted its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($5.68) earnings per share for the quarter, missing analysts' consensus estimates of ($5.26) by $0.42. During the same period in the prior year, the firm posted ($4.98) EPS.

What ETFs hold Madrigal Pharmaceuticals' stock?

ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) , Alger Mid Cap 40 ETF (FRTY) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Principal Healthcare Innovators ETF (BTEC) , SPDR S&P Biotech ETF (XBI) , iShares U.S. Pharmaceuticals ETF (IHE) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) and iShares Biotechnology ETF (IBB) .

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN) , Exelixis (EXEL) , Ayala Pharmaceuticals (ADXS) , Viking Therapeutics (VKTX) , Sangamo Therapeutics (SGMO) , Amarin (AMRN) , CRISPR Therapeutics (CRSP) , Intercept Pharmaceuticals (ICPT) , Sarepta Therapeutics (SRPT) and Gilead Sciences (gild) .

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rheos Capital Works Inc. (0.55%), Hennion & Walsh Asset Management Inc. (0.16%), AMI Asset Management Corp (0.05%), Congress Park Capital LLC (0.01%), Overbrook Management Corp (0.01%) and Sumitomo Mitsui Trust Holdings Inc. (0.00%). Insiders that own company stock include Brian Joseph Lynch , Bros Advisors Lp Baker, James M Daly, Paul A Friedman, Rebecca Taub, Remy Sukhija , Richard S Levy and Robert E Waltermire . View institutional ownership trends .

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free MDGL Stock Alerts

$212.04

-10.22 (-4.60%)

(As of 04/19/2024 ET)

Compare

Today's Range: $206.03
▼
$224.68
50-Day Range: $204.80
▼
$283.23
52-Week Range: $119.76
▼
$322.67

Volume: 625,155 shs
Average Volume: 337,309 shs
Market Capitalization: $4.22 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $377.40

Get Madrigal Pharmaceuticals alerts:

Madrigal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 78.0% Upside
$377.40 Price Target
Short Interest: Bearish
16.89% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.92
Upright™ Environmental Score
News Sentiment: 0.69
Based on 5 Articles This Week
Insider Trading: Selling Shares
$31.36 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($21.48) to ($13.50) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.57 out of 5 stars

Medical Sector

72nd out of 911 stocks

Pharmaceutical Preparations Industry

24th out of 419 stocks

4.5

Analyst's Opinion

Consensus Rating
Madrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Madrigal Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
16.89% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 6.
Change versus previous month
Short interest in Madrigal Pharmaceuticals has recently increased by 3.07%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Madrigal Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Madrigal Pharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Madrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Madrigal Pharmaceuticals is -0.92.

2.0

News and Social Media Coverage

News Sentiment
Madrigal Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Madrigal Pharmaceuticals this week, compared to 5 articles on an average week.
Search Interest
Only 35 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.
MarketBeat Follows
Only 25 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -7% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,362,420.00 in company stock.
Percentage Held by Insiders
23.92% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($21.48) to ($13.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Madrigal Pharmaceuticals is -10.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Madrigal Pharmaceuticals is -10.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Madrigal Pharmaceuticals has a P/B Ratio of 10.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

MDGL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MDGL Stock News Headlines

April 11, 2024 | insidertrades.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Rebecca Taub Sells 2,676 Shares

April 11, 2024 | insidertrades.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Paul A. Friedman Sells 26,270 Shares of Stock

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 9, 2024 | insidertrades.com

James M. Daly Sells 32,489 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock

April 6, 2024 | insidertrades.com

Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 18,710 Shares of Stock

April 4, 2024 | insidertrades.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Richard S. Levy Sells 11,000 Shares

March 28, 2024 | marketbeat.com

7 Stocks That Will Drive the Weight Loss Drugs Market (MDGL)

The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.

April 20, 2024 | msn.com

Madrigal Pharmaceuticals Welcomes New Employees with Equity Awards

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | globenewswire.com

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 15, 2024 | investorplace.com

7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024

April 12, 2024 | americanbankingnews.com

Rebecca Taub Sells 2,676 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock

April 12, 2024 | americanbankingnews.com

Paul A. Friedman Sells 26,270 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock

April 12, 2024 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rating Upgraded by StockNews.com

April 10, 2024 | msn.com

Madrigal Pharmaceuticals Launches Rezdiffra, a Pioneer in NASH Treatment

April 10, 2024 | msn.com

2 Under-the-Radar Growth Stocks to Consider

April 10, 2024 | fool.com

2 Under-the-Radar Growth Stocks to Consider

April 9, 2024 | finance.yahoo.com

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

April 7, 2024 | cnn.com

Madrigal Pharmaceuticals, Inc.

April 6, 2024 | msn.com

Madrigal Pharmaceuticals Awards Equity to New Employees as Inducement

April 5, 2024 | fool.com

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics

April 4, 2024 | finance.yahoo.com

Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares

April 4, 2024 | finance.yahoo.com

Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares

April 4, 2024 | finance.yahoo.com

Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares

April 3, 2024 | globenewswire.com

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 3, 2024 | fool.com

1 No-Brainer Growth Stock to Buy Now

April 2, 2024 | seekingalpha.com

Viking Therapeutics: Future Weight Loss Heavyweight?

See More Headlines

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:MDGL
CUSIP: 87162T20
CIK: 1157601
Web: www.madrigalpharma.com
Phone: (267) 824-2827
Fax: 781-274-8228
Employees: 376
Year Founded: 2011

Price Target and Rating

Average Stock Price Target: $377.40
High Stock Price Target: $425.00
Low Stock Price Target: $270.00
Potential Upside/Downside: +78.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($19.94)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-373,630,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -219.39%
Return on Assets: -98.75%

Debt

Debt-to-Equity Ratio: 0.28
Current Ratio: 5.38
Quick Ratio: 5.38

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $20.53 per share
Price / Book: 10.33

Miscellaneous

Outstanding Shares: 19,900,000
Free Float: 15,138,000
Market Cap: $4.22 billion
Optionable: Optionable
Beta: -0.47

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Rebecca A. Taub M.D. (Age 72)
Founder, Chief Medical Officer, President of Research & Development and Director
Comp: $939.83k
Mr. Brian J. Lynch J.D. (Age 62)
Senior VP & General Counsel
Comp: $763.75k
Mr. Alex G. Howarth (Age 55)
Executive Officer
Comp: $757.26k
Mr. William J. Sibold (Age 58)
CEO, President & Director
Ms. Mardi C. Dier (Age 60)
CFO, Principal Financial Officer, Principal Accounting Officer & Senior VP
Mr. Ronald Filippo
Chief Information Officer
Ms. Tina E. Ventura
Chief Investor Relations Officer
Dr. Kianoush Motesharei Ph.d. (Age 54)
Senior Vice President of Business & Corporate Development
Mr. Clint Wallace
Chief Human Resources Officer
Mr. Edward Chiang
Senior Vice President of Clinical & Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MDGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MDGL shares.
View MDGL analyst ratings or view top-rated stocks.
What is Madrigal Pharmaceuticals' stock price target for 2024?: 10 equities research analysts have issued 12 month price objectives for Madrigal Pharmaceuticals' stock. Their MDGL share price targets range from $270.00 to $425.00. On average, they expect the company's stock price to reach $377.40 in the next twelve months. This suggests a possible upside of 78.0% from the stock's current price.
View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts.
How have MDGL shares performed in 2024?: Madrigal Pharmaceuticals' stock was trading at $231.38 at the start of the year. Since then, MDGL stock has decreased by 8.4% and is now trading at $212.04.
View the best growth stocks for 2024 here.
When is Madrigal Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MDGL earnings forecast.
How were Madrigal Pharmaceuticals' earnings last quarter?: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) posted its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($5.68) earnings per share for the quarter, missing analysts' consensus estimates of ($5.26) by $0.42. During the same period in the prior year, the firm posted ($4.98) EPS.

What ETFs hold Madrigal Pharmaceuticals' stock?: ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Alger Mid Cap 40 ETF (FRTY), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), iShares U.S. Pharmaceuticals ETF (IHE), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and iShares Biotechnology ETF (IBB).
What other stocks do shareholders of Madrigal Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).
Who are Madrigal Pharmaceuticals' major shareholders?: Madrigal Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rheos Capital Works Inc. (0.55%), Hennion & Walsh Asset Management Inc. (0.16%), AMI Asset Management Corp (0.05%), Congress Park Capital LLC (0.01%), Overbrook Management Corp (0.01%) and Sumitomo Mitsui Trust Holdings Inc. (0.00%). Insiders that own company stock include Brian Joseph Lynch, Bros Advisors Lp Baker, James M Daly, Paul A Friedman, Rebecca Taub, Remy Sukhija, Richard S Levy and Robert E Waltermire.
View institutional ownership trends.
How do I buy shares of Madrigal Pharmaceuticals?: Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDGL) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

Madrigal Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

MDGL Stock Price History

MDGL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

MDGL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™